

Title: The public health control of scabies: priorities for research and action

Short title: Research priorities for scabies control

1

Authors:

Daniel Engelman, PhD

- a. Tropical Diseases, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
- b. Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
- c. General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia

Paul T Cantey, MD

Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland

Michael Marks, PhD

Clinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK

Anthony W Solomon, PhD

Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland

Aileen Y Chang, MD

Department of Dermatology, University of California San Francisco, San Francisco, California, USA

Prof Olivier Chosidow, PhD

- a. Department of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil, France;
- b. Université Paris-Est Créteil Val-de-Marne, Créteil, France.

Wendemagegn Enbiale, MD

Department of Dermatovenerology, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia

Dirk Engels, MD

United to Combat Neglected Tropical Diseases, Switzerland

Prof Roderick J Hay, DM

Department of Dermatology, King's College, London, United Kingdom

David Hendrickx, PhD

Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia

1

Prof Peter J Hotez, PhD
Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, USA

Prof John M Kaldor, PhD
The Kirby Institute, University of New South Wales, Sydney, Australia

Mike Kama, MBBS
Ministry of Health and Medical Services, Suva, Fiji

Prof Charles D Mackenzie, PhD
The Taskforce for Global Health, Decatur, Georgia, USA

Prof James S McCarthy, PhD
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

Diana L Martin, PhD
Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Birhan Mengitsu, MPH
Federal Ministry of Health, Addis Ababa, Ethiopia

Prof Toby Maurer, MD.
Department of Dermatology, University of California, San Francisco. San Francisco, California, USA

Nebiyu Negussu, MPH
Federal Ministry of Health, Addis Ababa, Ethiopia

Lucia Romani, PhD
The Kirby Institute, University of New South Wales, Sydney, Australia

Oliver Sokana, MPH
Ministry of Health and Medical Services, Honiara, Solomon Islands

Margot J Whitfeld, FACD
Department of Dermatology, St Vincent's Hospital, University of New South Wales, Sydney, Australia

L Claire Fuller, FRCP
a. Chelsea and Westminster Healthcare NHS Foundation Trust, London, UK
b. International Foundation for Dermatology, London, UK

Prof Andrew C Steer, PhD
a. Tropical Diseases, Murdoch Children's Research Institute, Melbourne, Victoria, Australia
b. Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
c. General Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia

Corresponding Author:

Daniel Engelman

Murdoch Children's Research Institute

50 Flemington Road, Parkville, Victoria, 3052, Australia

Phone: + 61 3 9345 5522

Fax: + 61 3 9345 6667

Email: Daniel.Engelman@rch.org.au

2 **Summary**

3 Scabies is a parasitic disease of the skin that disproportionately affects disadvantaged
4 populations. Scabies causes considerable morbidity and leads to severe bacterial infection and
5 immune-mediated disease. Recent scientific advances suggest that scabies is amenable to
6 population-level control, particularly through mass drug administration. In recognition of
7 these issues, WHO added scabies to the list of neglected tropical diseases (NTDs) in 2017. In
8 order to develop a global control program, key operational research questions must now be
9 addressed. Standardised approaches to diagnosis and methods for mapping are required to
10 further understand the burden of disease. The safety of treatments for young children,
11 including with ivermectin and moxidectin, should be investigated. Studies are needed to
12 inform optimum implementation of mass treatment, including the threshold for intervention,
13 target, dosing, and frequency. Frameworks for surveillance, monitoring and evaluation of
14 control strategies are also necessary.

15

16 **Introduction**

17 In 2017, scabies was added to the World Health Organization (WHO) list of neglected
18 tropical diseases (NTDs). Scabies was recommended to be included as a ‘category A’ NTD,
19 defined as those conditions that fulfil all four specified criteria, and are recommended for
20 large scale action in the portfolio of the NTD Department.¹ In reaching this recommendation,
21 the WHO NTD Strategic and Technical Advisory Group noted the need for further research
22 to inform control strategy as well as key issues for programmatic implementation, including
23 ensuring affordable access to oral medications and developing guidelines for their public
24 health use.² In March 2018, the WHO NTD Global Working Group on Monitoring and
25 Evaluation discussed scabies for the first time. Key recommendations from that meeting
26 included the need to better define the global burden; to integrate control efforts to capitalise
27 on ivermectin-based programs for other NTDs; and to establish interim guidelines for public
28 health interventions for scabies control.³ In this rapidly evolving context, we review major
29 recent advances in the science of control of human scabies, and identify key operational
30 research questions that need to be addressed to develop a global scabies control program.

31 **The burden of scabies**

32 Scabies is caused by infestation with the microscopic ectoparasite *Sarcoptes scabiei* var.
33 *hominis*, and leads to severe itch, skin lesions and more serious complications due to bacterial
34 superinfection (Figure 1). Transmission requires skin-to-skin contact, and there is no non-
35 human reservoir. Scabies occurs in all countries, but its distribution is not uniform. In high-
36 income settings, most cases are sporadic, and the predominant public health issue is the
37 management of outbreaks in institutions such as hospitals and residential aged care facilities.
38 A far greater burden of disease is found in low- and middle-income countries, where access
39 to effective treatment is limited and population crowding increases the opportunities for
40 transmission. Areas with hot, humid climates have the highest reported prevalence, most
41 prominently island communities in the Pacific region and Central America, and Indigenous
42 communities of northern Australia.⁴⁻⁶ In these settings, the community prevalence has been
43 consistently estimated in the range of 20 – 30%, with a higher prevalence of up to 40 – 50%
44 in children aged less than 18 years (Figure 2).⁷⁻⁹

45 In other resource-limited settings where baseline prevalence is lower, change in
46 environmental or socio-political conditions can be associated with epidemics,¹⁸ such as the

47 outbreak in the Amhara Region in Ethiopia that has been in progress since 2015 and has been
48 estimated to affect more than one million people.^{19,20} Circumstances with substantial
49 population crowding frequently lead to high levels of transmission, and outbreaks are
50 common within schools, prisons and camps for refugees and internally displaced persons.²¹

51 Scabies is one of the world's most common illnesses. The Global Burden of Disease (GBD)
52 Study 2016 estimated the global point prevalence of scabies to be around 147 million, with
53 455 million annual incident cases.²² Further GBD analyses estimated that scabies caused
54 approximately 3.8 million disability-adjusted life years (DALYs), ranking scabies as one of
55 the most important NTDs.²³ Scabies causes an age-adjusted morbidity burden similar to
56 *Haemophilus influenzae* type B meningitis and acute lymphoid leukaemia.²⁴ These GBD
57 analyses are modelled on the small number of published reports on the prevalence of scabies.
58 Of note, the disability weighting only considers the skin changes and itch directly caused by
59 infestation.²⁴ The estimated burden would be far greater if the morbidity and mortality caused
60 by the complications of scabies were included (Figure 3). Scabies infestation causes a
61 considerable proportion of bacterial skin infection (pyoderma) in many resource-limited
62 settings, most commonly manifesting as infected sores (impetigo).^{7,8,25,26} For example,
63 Aboriginal children in Australia were 12 times more likely to develop impetigo when
64 infected with the scabies mite,²⁶ and studies from Pacific island nations have estimated the
65 attributable risk of scabies as a cause of impetigo to be 41% – 93%.^{7,8,27} Scabetic lesions and
66 traumatic scratching create breaches in the skin barrier that are a portal for bacterial entry.
67 Scabies mite components such as serpins inhibit innate immune pathways including
68 neutrophil function and directly promote the growth of *Staphylococcus aureus* and
69 *Streptococcus pyogenes*.²⁸⁻³¹ Skin infection due to these bacteria can lead to severe soft
70 tissue infections and invasive disease. Infection with *S. pyogenes* can also lead to immune-
71 mediated complications including post-streptococcal glomerulonephritis and possibly acute
72 rheumatic fever, which in turn contribute to chronic kidney disease and rheumatic heart
73 disease (Figure 3).^{32,33} Quantification of the proportion of the burden of these serious health
74 consequences attributable to scabies will give a more accurate estimate of the global burden
75 of scabies and the potential benefit of scabies control.

76 **Diagnosis**

77 Both the mapping of scabies and population-level control are hampered by the lack of a
78 reliable, reproducible and standardised approach to diagnosis. Two systematic reviews of

79 diagnostic methods found a lack of consistency in the approach to scabies diagnosis.^{34,35}
80 Microscopy of skin scrapings to visualise mites and eggs is highly specific but insensitive and
81 operator dependent, and therefore generally not useful for field settings. In order to address
82 this gap, an international panel of experts, convened by the International Alliance for the
83 Control of Scabies (IACS) recently used a Delphi consensus method to develop the 2018
84 IACS Criteria for Scabies Diagnosis in research and epidemiological settings.³⁶ These criteria
85 enable diagnosis and reporting in three bands of diagnostic certainty - confirmed, clinical and
86 suspected scabies. A diagnosis of confirmed scabies requires identification of the mite on
87 microscopy or non-invasive visualisation techniques such as videomicroscopy and
88 dermoscopy.³⁷ Clinical and suspected scabies categories rely on features of clinical history
89 and examination. As such, the criteria can be adapted for use in a variety of settings,
90 including field surveys, and may help to standardise reporting and the conduct of scabies
91 research. Validation of these criteria in diverse environments is now required, followed by
92 development of standardised training methods and materials.

93 Although the current focus should be on development of diagnostics for mapping and
94 surveillance, in future, objective diagnostic tests may be needed, particularly if areas of low-
95 endemicity transition to a target of disease elimination. A point-of care diagnostic test would
96 be ideal for public health use. Direct skin-based testing for infestation using molecular
97 techniques, including polymerase chain reaction^{38,39} and loop mediated isothermal
98 amplification,⁴⁰ have been proposed but none are currently ready for programmatic use.
99 Development of ELISA-based tests to detect antibodies against scabies antigens⁴¹ has been
100 hindered by cross-reactivity between antigens from scabies and house dust mites.^{42,43} If a
101 specific antibody test for scabies was developed, in order for it to be diagnostic, further
102 evaluation would need to ensure that measured antibody responses were directly associated
103 with ongoing infestation and not a measure of previous exposure.

104 In addition to molecular diagnostics, non-invasive mite visualisation methods should be
105 further evaluated. These high-magnification methods allow direct, in vivo visualisation of the
106 mite (and with some methods, determination of mite survival or demise after treatment)
107 without extraction of the mite by skin-scraping.^{44,45} Although these devices are expensive and
108 require specialised training, more simple and affordable videomicroscopes also permit
109 accurate visualisation of the mite in vivo, and low cost dermatoscopes have been
110 developed.^{46,47} Further investigation and standardisation of outcome measures using these

111 methods would assist in assessing the efficacy of new treatments, and possibly validation of
112 mapping and confirmation of outbreaks.⁴⁸

113 **Epidemiology and mapping**

114 Despite an expansion of research on scabies in the last decade, the development of a global
115 strategy has been constrained by a lack of prevalence data from most countries, including
116 those suspected to be at-risk based on routinely reported clinical data or geographic or
117 socioeconomic characteristics. For example, a worldwide systematic review of published
118 scabies prevalence estimates found 48 studies, of variable quality, with over-representation of
119 countries in the Pacific region and large areas of the world having no published prevalence
120 data.⁴ Experience from other NTDs suggests that the knowledge of disease burden gained
121 through mapping is critical for stakeholder engagement, translational research and successful
122 scale-up of control programs.⁴⁹

123 Given the logistic challenge and cost of detailed mapping for NTDs,⁵⁰ a priority activity is the
124 development of a simple, low-cost, rapid assessment tool to assist policy-makers in initially
125 determining whether scabies is likely to be a public health problem in a given context.
126 Standardised survey methods to map scabies prevalence would then be required for a more
127 detailed estimate of disease burden and its variation within and between regions. Survey
128 methods could utilise the 2018 IACS Diagnostic criteria,³⁶ if these criteria are found to be
129 valid and reproducible. It may be possible to train non-expert examiners in a limited, brief
130 skin examination, which could then be correlated with more detailed diagnostic methods.⁵¹ A
131 similar approach has been used for trachoma, where a rapid assessment may be followed by a
132 standardised mapping survey.⁵²⁻⁵⁵ Survey design will need to consider the most appropriate
133 populations and settings in which to conduct mapping, including ease of access, spatial and
134 age distributions of disease and community acceptability. For example, mapping of children
135 attending school could be expected to provide a representation of the groups with the highest
136 burden in a community. This may be efficient, practicable and amenable to integration with
137 mapping for some other NTDs and other health and education programs.^{56,57} Formal
138 comparison of school versus community based sampling would help determine how well
139 school prevalence correlates with community prevalence.^{58,59}

140 Beyond national-level prevalence data, there is limited understanding of the epidemiology of
141 specific high burden areas or populations within otherwise high-income or low-prevalence

142 settings. Recognized examples include disadvantaged Indigenous populations within
143 Australia, New Zealand and Canada,^{26,60-62} imprisoned ^{63,64} and homeless populations,⁶⁵ and
144 among groups seeking asylum within Europe.⁶⁶⁻⁶⁸ Scabies is a disease of poverty and inequity
145 and it is likely that sub-populations with higher burdens would be found in many otherwise
146 high-income settings.⁶⁹

147 Institutional scabies outbreaks result in considerable morbidity, stigma and healthcare cost in
148 high-income settings. These outbreaks are typically challenging to identify and manage,
149 leading to lengthy delays in confirmation and control as well as substantial cost.⁷⁰⁻⁷³ Changes
150 in social demography, particularly aging, mean that these outbreaks may become more
151 common, and the development of appropriate public health strategies is therefore warranted.
152 A deeper appreciation of the features of institutional outbreaks in high-income settings could
153 be leveraged for control of scabies elsewhere.

154 **Transmission and complications**

155 Despite scabies being an ancient disease, our understanding of the drivers of transmission
156 remains limited. Understanding transmission dynamics is important for investigating the
157 comparative effects of different control strategies, including through mathematical
158 modelling.^{74,75} The observed cycles of scabies prevalence in some temperate settings (leading
159 to the misnomer “the seven-year itch”) previously raised the possibility of herd immunity.
160 However, in many tropical settings, recurrent infestations are common and present with more
161 rapid onset of symptoms than in the initial infection.⁴³ Very high population prevalence is
162 sustained in some of these settings, suggesting that variations across geographic regions and
163 time are more likely explained by factors other than personal or herd immunity.^{76,77}

164 Of particular importance to transmission is the role of individuals with the rare clinical
165 variant of crusted scabies (previously known as Norwegian scabies), usually in association
166 with immunosuppression (disease or drug-related) or neurological illness. People with
167 crusted scabies may carry thousands to millions of mites and are highly infectious, thereby
168 acting as core transmitters within some communities.⁷⁸ Failure to identify and manage these
169 individuals may undermine the success of control programs.⁷⁹ There is an incomplete
170 understanding of why there are many individuals in northern Australia with crusted scabies in
171 the absence of identifiable causes of immunosuppression, but relatively few such cases have
172 been described in other high-prevalence settings.^{7,78,80,81}

173 The pathogenic links between scabies, impetigo, the infectious complications of *S. aureus*
174 and *S. pyogenes* and the immune-mediated complications of *S. pyogenes* need further
175 investigation. If these high morbidity and mortality conditions can be more definitively
176 linked with scabies, and can be shown to be effectively prevented through scabies control, the
177 rationale to invest in scabies control will be more compelling for governments, potential
178 donors and other stakeholders. The relevant associations have been considered most
179 thoroughly in the Pacific region,^{61,82-84} where impetigo is very common, but the limited data
180 from other regions suggest endemic scabies occurs in those environments with lower
181 prevalence of impetigo.⁴ This pattern needs to be properly quantified and the reasons for any
182 variation, if genuinely present, further explored. Impetigo caused by *S. pyogenes* is a major
183 cause of acute glomerulonephritis,⁸⁵ which in turn contributes to the high burden of chronic
184 kidney disease in low-income settings.⁸⁶ Scabies has been associated with chronic kidney
185 disease in both epidemiological studies and case reports.⁸⁷⁻⁸⁹ Rheumatic heart disease is
186 estimated to cause over 300,000 deaths per year, with a global distribution that overlaps with
187 areas highly-endemic for scabies.⁹⁰ A global resolution on rheumatic fever and rheumatic
188 heart disease was adopted by the World Health Assembly in 2018.⁹¹ Primary prevention of
189 streptococcal skin infection through scabies control could potentially be an important
190 component of preventing these diseases.⁶¹

191 **Social and economic issues**

192 As a disease that affects the skin, scabies is a potent cause of stigma and reduced quality of
193 life.^{11,92,93} Increasingly, the chronic disfigurement caused by scabies and other NTDs is
194 understood to adversely affect mental health,^{56,94} although this aspect has not been factored
195 into current GBD estimates of DALYs. Understanding the conception of scabies, itch and
196 impetigo within various cultures will help define what ‘scabies as a public health problem’
197 means to the most affected communities. This research will also assist in building
198 partnerships with communities to develop control intervention, and to maximise participation
199 in them. Scabies is often incorrectly attributed to ‘poor hygiene,’ which may lead to stigma,
200 shame and reduced health-seeking. However, hygiene and handwashing do not affect the mite
201 or transmission,⁹⁵ and highly effective control has been demonstrated without any measures
202 addressing hygiene or environment (see below),⁹⁶ suggesting that associations with situations
203 of poverty and disadvantage are likely due to poor access to healthcare and treatment, or the
204 effects of overcrowding.^{21,97} The economic burden of scabies in some areas is thought to be

205 substantial, particularly due to the infestation leading to absence from employment and
206 education, as well as the direct costs of accessing healthcare and repeated treatments (Figure
207 3).⁹⁸ Economic studies of the costs of scabies infestation and complications are needed to
208 define and advocate for the most cost-effective control strategies.

209 **Treatment**

210 Although there are a number of effective, topical preparations for treatment of individual
211 cases, for multiple reasons these agents are poorly suited to population-level control
212 interventions. Reasons include the prolonged duration of application required and local
213 irritation, resulting in inadequate adherence.⁹⁹ Permethrin 5% cream is the most effective
214 topical treatment,¹⁰⁰ but is expensive and unavailable in most countries.²¹ Topical treatments
215 that are available in some low- and middle-income countries include benzyl benzoate and
216 sulphur ointments, but these are less well tolerated. Both options commonly cause skin
217 irritation and stinging after application, and sulphur ointments are messy, malodourous and
218 require repeat treatments.²¹ The effectiveness and safety profile of novel topical agents,
219 including tea tree oil, for individual case management should be further explored.¹⁰¹⁻¹⁰⁸

220 Oral medicines have clear advantages for treatment of asymptomatic individuals, and
221 particularly for treatment of whole populations through mass drug administration (MDA),
222 where oral medications are more likely to be accepted and ingestion can be directly observed.
223 Oral ivermectin is highly effective against scabies. Due to the lack of ovicidal action, a
224 second treatment is usually recommended after 7-14 days for individual treatment, to kill
225 newly hatched mites. A recent Cochrane review did not find any difference in efficacy when
226 one dose was compared with two doses of ivermectin, or between oral ivermectin and topical
227 permethrin.¹⁰⁹ Although the strength of the review conclusions was limited by the quality of
228 included studies, available evidence suggests that a single dose of ivermectin has some
229 efficacy, and that two doses are likely to be comparably effective to permethrin for individual
230 treatment. There is extensive experience on the feasibility and safety of using ivermectin for
231 MDA for other NTDs such as lymphatic filariasis and onchocerciasis.¹¹⁰

232 An oral agent with a longer duration of activity in the skin, that could persist for sufficient
233 time to kill newly hatched mites, would obviate the need for a second dose and represent a
234 major advance. Slow-release formulations of ivermectin have been developed, providing
235 potential therapeutic effect for up to 6 months.¹¹¹ These warrant further investigation for

236 scabies, although if the dosage form is large, administration to children may be challenging.
237 Moxidectin, a macrocyclic lactone anti-parasitic agent related to ivermectin, has a half-life of
238 up to 43 days, with prolonged activity in the skin.^{112,113} It is effective against *Sarcoptes*
239 infestations in animals, and in a pre-clinical trial using a porcine-model of scabies, single
240 dose moxidectin was superior to two doses of ivermectin based on the primary outcome
241 measure of mite score.¹¹⁴ Moxidectin has recently been approved by the United States Food
242 and Drug Administration (FDA) for treatment of onchocerciasis in individuals aged 12 years
243 and above.¹¹⁵ Clinical trials of moxidectin for scabies have now commenced, with a plan to
244 develop palatable products for children.¹¹⁶

245 Research into scabies treatments also needs to consider safety, including treatment of
246 pregnant and breastfeeding women and small children, groups that carry a disproportionate
247 burden of scabies and are responsible for much its transmission. Administration of topical
248 treatment to these groups during ivermectin-based MDA is a major cost and logistic issue.
249 Due to the inadequacy of existing safety data, use of ivermectin in MDA programs for other
250 NTDs has been restricted to those weighing over 15 kg or measuring above 90 cm (or aged 5
251 years or older in some settings). It is worth noting, however, that several studies have
252 reported no significant adverse outcomes from clinical and inadvertent public health use in
253 young children.^{117,118} Further investigation of the safety of ivermectin in young children, and
254 prospective data on the safety of moxidectin, are priorities. Ivermectin is considered a
255 pregnancy category C drug by the FDA, but this determination is based on animal studies that
256 used doses far in excess of those recommended for people.¹¹⁹ Studies comparing inadvertent
257 treatment in pregnant women to controls have not demonstrated any concerning safety
258 signal.¹²⁰⁻¹²³ In other NTD programs, ivermectin is offered when the risk of disease is
259 considered higher than the theoretical risk to the foetus.¹²⁴ In France, ivermectin is a
260 recommended second-line treatment for scabies during pregnancy.¹²⁵ Ivermectin is excreted
261 in very low concentrations in human milk, and is generally regarded as safe in lactating
262 women after the infant is 7 days old. Ivermectin can cause serious adverse events in
263 individuals with high blood counts of *Loa Loa* microfilariae, a parasite found in Central
264 Africa. Development of new diagnostic technologies such as the Loascope may enable safe
265 delivery of ivermectin MDA in these areas,¹²⁶ but further investigation of implementation is
266 needed.¹²⁷

267 In order to capitalise on existing MDA platforms for other NTDs, the safety of co-
268 administration of ivermectin with other medications needs to be established. In addition to the
269 long-standing practice of co-administration with albendazole, large-scale studies have now
270 demonstrated the safety of co-administration with azithromycin, opening the possibility of
271 integrating control of scabies with control of yaws and/or trachoma.¹²⁸⁻¹³⁰ Similarly, early
272 analysis of a multi-national safety cohort study of combination therapy of ivermectin,
273 diethylcarbamazine and albendazole (IDA) for lymphatic filariasis did not reveal safety
274 concerns and administration of this combination of agents has now been recommended for
275 specific epidemiological contexts within WHO guidelines.¹³¹⁻¹³⁴

276 Monitoring for development of resistance of mites to acaricides will also be important. There
277 have been isolated case reports of resistance to ivermectin in patients with crusted scabies
278 who received repeated and prolonged treatment.¹³⁵⁻¹³⁷ Annual MDA may be less likely to
279 promote the development of resistance than repeated individual treatments, but there is a lack
280 of evidence on this subject.¹³⁸ The proposed use of ivermectin MDA for malaria control^{119,139}
281 could also promote resistance, particularly if a strategy of multiple doses each month is
282 used.¹⁴⁰ However, the risk of resistance seems to be greater for intestinal helminths than
283 ectoparasites, based on experiences in livestock, where resistance to ivermectin among
284 intestinal parasites is now widespread.^{141,142} Increasing use of topical treatments for other
285 conditions in humans, such as permethrin for head lice and topical ivermectin for rosacea,
286 may also promote resistance in scabies mites.¹⁴³

287 Detailed treatment guidelines for scabies have been developed in several high-income
288 countries and regions, but recommendations vary.¹⁴⁴⁻¹⁴⁶ Standardised, evidence-based
289 treatment guidelines for resource-limited settings, including individual case management and
290 management of outbreaks in institutions or closed communities, would be valuable. Further
291 investigation and development of guidelines for the appropriate treatment for individuals with
292 crusted scabies in these settings, would also facilitate the success of control
293 interventions.^{81,147-149}

294 **Population-level control**

295 The strategy of individual case management has failed to appreciably reduce the transmission
296 of scabies in high-prevalence settings.^{6,150} Recent data from studies using MDA have led to
297 renewed interest in the potential of MDA to contribute to sustained population-level

298 control.^{151,152} Programs of mass treatment combined with additional screening and case
299 management in Panama and Australia (using permethrin)^{6,9,153} and the Solomon Islands
300 (using ivermectin)¹⁵⁴ considerably reduced scabies prevalence. Indirect evidence from
301 Zanzibar suggested a reduction in consultations and prescriptions for scabies following
302 annual MDA of ivermectin and albendazole for lymphatic filariasis^{155,156} but a study from a
303 lower prevalence setting in mainland Tanzania did not show a sustained effect.¹⁵⁷ However,
304 in lymphatic filariasis control programs, children under 5 years are not given ivermectin (or
305 any other agent active against scabies), which may explain ongoing transmission in this
306 context. The only controlled trial of community treatment published to date was conducted
307 in small, relatively isolated island populations in Fiji, where a single round of ivermectin-
308 based MDA reduced the prevalence of scabies by 94%, in comparison to the permethrin-
309 based MDA (62% reduction) and screen-and-refer arms (49% reduction).¹⁵⁸ These effects
310 have now been shown to be sustained up to 24 months post intervention.¹⁵⁹ The ivermectin-
311 based MDA intervention also resulted in a reduction of impetigo of 67% without adjunctive
312 mass antibiotic treatment. Further work in the Solomon Islands using ivermectin-based MDA
313 in a much larger population reported reductions in scabies prevalence of around 90%, and in
314 impetigo prevalence of around 75%.^{14,130} Conversely, ivermectin-based MDA for scabies in
315 northern Australia was not associated with a sustained reduction in prevalence.⁷⁹ The
316 different results observed in the Australian study may have been due to increased interactions
317 with surrounding untreated communities; lower baseline prevalence (4%, as compared to 32-
318 42% in the Fiji study); and transmission from untreated individuals with crusted scabies.

319 These studies set the scene for further investigation of the role of programmatic MDA in
320 scabies control. Priority future studies include investigation of whether a single dose of
321 ivermectin (as opposed to two doses, 7 to 14 days apart) is sufficiently effective as MDA for
322 scabies, and investigation of ivermectin-based MDA in other settings, including non-island
323 populations where population mobility may be greater. While existing MDA data suggest
324 effectiveness at high or very high population prevalence of 10 to 40%, the relative roles of
325 MDA and case management at lower prevalence, for example, less than 10%, have not yet
326 been adequately explored. Investigating the effect of MDA for scabies on complications such
327 as skin and soft tissue infection, sepsis and autoimmune sequelae will be important, but
328 require a large sample size and significant investment in infrastructure for active surveillance.
329 Studies of moxidectin-based MDA should also be prioritised, if initial individually
330 randomised clinical trials demonstrate efficacy.

331 Implementation research of integration of scabies control with other NTDs, particularly those
332 affecting the skin, has the potential to demonstrate cost-efficient delivery of multiple health
333 interventions.^{56,160} Initial studies could focus on understanding the impact of ivermectin-
334 based MDA for onchocerciasis and lymphatic filariasis on the prevalence of scabies in areas
335 that are scaling up treatment, as well as the effect of cessation of MDA in areas that are
336 scaling down treatment. There is concern that as ivermectin use for these programs is rolled
337 back in some countries, there could be a resurgence of scabies infestation, which may be a
338 major unintended consequence for communities. An additional research priority will be to
339 investigate the feasibility and impact of adding topical scabies treatment of young children to
340 existing ivermectin-based NTD programs. The possibility of developing a scabies vaccine has
341 been considered, although this approach is still at an early stage of development.^{43,161,162}

342 **Developing a global strategy**

343 Despite some deficiencies in the evidence for scabies control strategies, there is a need to
344 develop preliminary recommendations that can be implemented by countries wishing to
345 commence control measures, alongside pursuit of the research agenda described above. Initial
346 guidance is required on the threshold of scabies prevalence above which MDA could be
347 recommended, and other health system-related, geographic, socio-political or pragmatic
348 factors that might affect this decision. In lower-prevalence settings, intensified case
349 management strategies may be more appropriate. If MDA is to be utilised at large scale, then
350 guidance will be required on the control target, number and frequency of MDA rounds, and
351 monitoring and surveillance plan, including post-MDA surveillance, drawing on the lessons
352 from other NTDs.¹⁶³ This initial guidance should draw on the existing evidence-base, and—
353 acknowledging the limitations of current data—expert opinion and modelling work, with
354 plans made for guidance to be refined as further evidence becomes available. If sustained
355 control can be demonstrated, then it may be appropriate to consider the possibility of
356 elimination (interruption of transmission) at a national or regional level.

357 Once a mapping strategy is developed as part of a global control strategy, it will be possible
358 to estimate the at-risk population requiring ivermectin and permethrin within individual
359 countries and, with less certainty, at regional and global levels. Individual countries would be
360 able to develop control plans as part of broader NTD strategies, taking into consideration the
361 relative burden of scabies and other health issues.

362 It will be essential to advocate for access to affordable, quality-assured medications.
363 Ivermectin has been generously donated through the Mectizan Donation Program for
364 onchocerciasis and lymphatic filariasis in Africa and Latin America. This donation has
365 recently expanded for use in countries where onchocerciasis is not endemic, as part of the
366 IDA treatment strategy for lymphatic filariasis elimination.¹⁶⁴ However, it is unclear if such a
367 program could be extended to include scabies control as an indication. Although a donation
368 program would maximise the likelihood of achieving control, low-cost, high-quality generic
369 ivermectin may also be affordable in some settings. In addition to advocacy for donations,
370 manufacturers of generic ivermectin could be supported to apply for WHO pre-qualification.³
371 There is no precedent for a donation program for permethrin, and considerable amounts of it
372 would be required for treatment of individuals for whom ivermectin is contraindicated. The
373 licence holders of moxidectin, Medicines Development for Global Health, have committed to
374 providing moxidectin at an affordable price for scabies control in low- and middle-income
375 countries, if efficacy is demonstrated.¹¹⁶

376 **Conclusions**

377 Scabies is a common illness and major health issue affecting communities in many resource-
378 limited settings, and warrants public health intervention. There is strong evidence that
379 ivermectin-based MDA strategies can be highly effective in reducing the burden of scabies
380 and impetigo in at least some settings. Future research priorities include further defining the
381 burden of disease, developing standardised approaches to diagnosis and population burden
382 estimation, novel diagnostics and treatments, and evaluating large-scale community control
383 strategies. Interim guidance on scabies control is now required.

384

385 **Contributors**

386 D. Engelman and ACS conceived of the project. D. Engelman searched and reviewed the
387 literature, wrote the first draft of the manuscript, made revisions and prepared Figure 3. D.
388 Engelman, LR, MJW, JMK and ACS reviewed prevalence data for Figure 2. D. Engelman,
389 PTC, MM, AWS, JMK and ACS contributed to further development of the structure and
390 content. All authors reviewed drafts of the manuscript, provided comments and critical
391 review, helped to revise the manuscript and agreed to the final version.

392

393 **Declaration of Interests**

394 Prof. Chosidow reports personal fees from Codexial and Zambon. All other authors declare
395 they have no competing interests.

396

397 **Acknowledgments**

398 D. Engelman, LR, JMK and ACS were supported by Australian National Health and Medical
399 Research Council Fellowships. ACS was also supported by the National Heart Foundation of
400 Australia. MM was supported by the UK National Institute of Health Research. We
401 acknowledge the contributions of Patrick Lammie and Aya Yajima to the ideas contained in
402 this manuscript. Karly Cini assisted with preparation of Figure 2. PTC and AWS are
403 employees of WHO. DLM is an employee of the Centers for Disease Control and Prevention
404 (CDC). The findings and opinions expressed in this paper are those of the authors and do not
405 necessarily represent the views, decisions or policies of WHO, the CDC or other institutions
406 with which the authors are affiliated.

407

408

409

410 **References**

- 411 1. WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases.
412 Recommendations for the adoption of additional diseases as neglected tropical diseases.
413 2016. http://www.who.int/neglected_diseases/diseases/Adoption_additional_NTDs.pdf
414 (accessed May 12, 2018).
- 415 2. World Health Organization. Report of the tenth meeting of the WHO Strategic and
416 Technical Advisory Group for neglected tropical diseases. 2017.
417 http://www.who.int/neglected_diseases/NTD_STAG_report_2017.pdf?ua=1 (accessed 17
418 March 2018).
- 419 3. World Health Organization. 9th NTD-STAG Global Working Group Meeting on
420 Monitoring and Evaluation of Neglected Tropical Diseases. World Health Organisation,
421 2018.
- 422 4. Romani L, Steer AC, Whitfeld MJ, Kaldor JM. Prevalence of scabies and impetigo
423 worldwide: a systematic review. *Lancet Infect Dis* 2015; **15**(8): 960-7.
- 424 5. Bowen AC, Mahe A, Hay RJ, et al. The Global Epidemiology of Impetigo: A
425 Systematic Review of the Population Prevalence of Impetigo and Pyoderma. *PLoS One* 2015;
426 **10**(8): e0136789.
- 427 6. Taplin D, Porcelain SL, Meinking TL, et al. Community control of scabies: a model
428 based on use of permethrin cream. *Lancet* 1991; **337**(8748): 1016-8.
- 429 7. Romani L, Koroivueta J, Steer AC, et al. Scabies and impetigo prevalence and risk
430 factors in Fiji: a national survey. *PLoS Negl Trop Dis* 2015; **9**(3): e0003452.
- 431 8. Mason DS, Marks M, Sokana O, et al. The prevalence of scabies and impetigo in the
432 solomon islands: A population-based survey. *PLoS Negl Trop Dis* 2016; **10**(6): e0004803.
- 433 9. Carapetis JR, Connors C, Yarmirr D, Krause V, Currie BJ. Success of a scabies
434 control program in an Australian aboriginal community. *Pediatr Infect Dis J* 1997; **16**(5):
435 494-9.
- 436 10. Korte LM, Bowen AC, Draper ADK, et al. Scabies and impetigo in Timor-Leste: A
437 school screening study in two districts. *PLoS Negl Trop Dis* 2018; **12**(5): e0006400.
- 438 11. Walker SL, Lebas E, De Sario V, et al. The prevalence and association with health-
439 related quality of life of tungiasis and scabies in schoolchildren in southern Ethiopia. *PLoS*
440 *Negl Trop Dis* 2017; **11**(8): e0005808.

- 441 12. Yotsu RR, Kouadio K, Vagamon B, et al. Skin disease prevalence study in
442 schoolchildren in rural Cote d'Ivoire: Implications for integration of neglected skin diseases
443 (skin NTDs). *PLoS Negl Trop Dis* 2018; **12**(5): e0006489.
- 444 13. Kouotou EA, Nansseu JR, Kouawa MK, Zoung-Kanyi Bissek AC. Prevalence and
445 drivers of human scabies among children and adolescents living and studying in
446 Cameroonian boarding schools. *Parasit Vectors* 2016; **9**(1): 400.
- 447 14. Romani L, Marks M, Sokana O, et al. Efficacy of mass drug administration with
448 ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a
449 single-arm community intervention trial. *Lancet Infect Dis* 2019.
- 450 15. Ugbomoiko US, Oyedeji SA, Babamale OA, Heukelbach J. Scabies in Resource-Poor
451 Communities in Nasarawa State, Nigeria: Epidemiology, Clinical Features and Factors
452 Associated with Infestation. *Trop Med Infect Dis* 2018; **3**(2).
- 453 16. Martin D, Wiegand R, Goodhew B, Lammie P, Mkocho H, Kasubi M. Impact of
454 Ivermectin Mass Drug Administration for Lymphatic Filariasis on Scabies in Eight Villages
455 in Kongwa District, Tanzania. *Am J Trop Med Hyg* 2018; **99**(4): 937-9.
- 456 17. Hegab DS, Kato AM, Kabbash IA, Dabish GM. Scabies among primary
457 schoolchildren in Egypt: sociomedical environmental study in Kafr El-Sheikh administrative
458 area. *Clin Cosmet Investig Dermatol* 2015; **8**: 105-11.
- 459 18. Dayrit JF, Bintanjoyo L, Andersen LK, Davis MDP. Impact of climate change on
460 dermatological conditions related to flooding: update from the International Society of
461 Dermatology Climate Change Committee. *Int J Dermatol* 2018; **57**(8): 901-10.
- 462 19. WHO Africa. Ethiopia - Scabies outbreak response in Amhara regional state.
463 <https://www.afro.who.int/news/ethiopia-scabies-outbreak-response-amhara-regional-state>
464 (accessed 6 July 2018).
- 465 20. Enbiale W, Ayalew A. Investigation of a Scabies Outbreak in Drought-Affected
466 Areas in Ethiopia. *Trop Med Infect Dis* 2018; **3**(4).
- 467 21. Hay RJ, Steer AC, Engelman D, Walton S. Scabies in the developing world--its
468 prevalence, complications, and management. *Clin Microbiol Infect* 2012; **18**(4): 313-23.
- 469 22. Global, regional, and national incidence, prevalence, and years lived with disability
470 for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the
471 Global Burden of Disease Study 2016. *Lancet* 2017; **390**(10100): 1211-59.
- 472 23. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases
473 and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016:

- 474 a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;
475 **390**(10100): 1260-344.
- 476 24. Karimkhani C, Colombara DV, Drucker AM, et al. The global burden of scabies: a
477 cross-sectional analysis from the Global Burden of Disease Study 2015. *Lancet Infect Dis*
478 2017; **17**(12): 1247-54.
- 479 25. Tasani M, Tong SY, Andrews RM, et al. The Importance of Scabies Coinfection in
480 the Treatment Considerations for Impetigo. *Pediatr Infect Dis J* 2016; **35**(4): 374-8.
- 481 26. Aung PTZ, Cuningham W, Hwang K, et al. Scabies and risk of skin sores in remote
482 Australian Aboriginal communities: A self-controlled case series study. *PLoS Negl Trop Dis*
483 2018; **12**(7): e0006668-e.
- 484 27. Thornley S, Sundborn G, Arbuckle M, Loring B, Heather M, Reynolds E. Is impetigo
485 a missed opportunity for scabies treatment? *N Z Med J* 2018; **131**(1481): 78-81.
- 486 28. Swe PM, Reynolds SL, Fischer K. Parasitic scabies mites and associated bacteria
487 joining forces against host complement defence. *Parasite Immunol* 2014; **36**(11): 585-93.
- 488 29. Reynolds SL, Pike RN, Mika A, et al. Scabies mite inactive serine proteases are
489 potent inhibitors of the human complement lectin pathway. *PLoS Negl Trop Dis* 2014; **8**(5):
490 e2872.
- 491 30. Swe PM, Fischer K. A scabies mite serpin interferes with complement-mediated
492 neutrophil functions and promotes staphylococcal growth. *PLoS Negl Trop Dis* 2014; **8**(6):
493 e2928.
- 494 31. Swe PM, Zakrzewski M, Kelly A, Krause L, Fischer K. Scabies mites alter the skin
495 microbiome and promote growth of opportunistic pathogens in a porcine model. *PLoS Negl*
496 *Trop Dis* 2014; **8**(5): e2897.
- 497 32. Engelman D, Kiang K, Chosidow O, et al. Toward the global control of human
498 scabies: introducing the International Alliance for the Control of Scabies. *PLoS Negl Trop*
499 *Dis* 2013; **7**(8): e2167.
- 500 33. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart
501 disease. *Curr Opin Infect Dis* 2012; **25**(2): 145-53.
- 502 34. Leung V, Miller M. Detection of scabies: a systematic review of diagnostic methods.
503 *Can J Infect Dis Med Microbiol* 2011; **22**(4): 143-6.
- 504 35. Thompson MJ, Engelman D, Gholam K, Fuller LC, Steer AC. Systematic review of
505 the diagnosis of scabies in therapeutic trials. *Clin Exp Dermatol* 2017; **42**(5): 481-7.
- 506 36. Engelman D, Fuller LC, Steer AC. Consensus criteria for the diagnosis of scabies: A
507 Delphi study of international experts. *PLoS Negl Trop Dis* 2018; **12**(5): e0006549.

- 508 37. Micali G, Lacarrubba F, Verzi AE, Chosidow O, Schwartz RA. Scabies: Advances in
509 Noninvasive Diagnosis. *PLoS Negl Trop Dis* 2016; **10**(6): e0004691.
- 510 38. Hahm JE, Kim CW, Kim SS. The efficacy of a nested polymerase chain reaction in
511 detecting the cytochrome c oxidase subunit 1 gene of *Sarcoptes scabiei* var. *hominis* for
512 diagnosing scabies. *Br J Dermatol* 2018.
- 513 39. Angelone-Alasaad S, Molinar Min A, Pasquetti M, et al. Universal conventional and
514 real-time PCR diagnosis tools for *Sarcoptes scabiei*. *Parasit Vectors* 2015; **8**: 587.
- 515 40. Fraser TA, Carver S, Martin AM, Mounsey K, Polkinghorne A, Jelocnik M. A
516 *Sarcoptes scabiei* specific isothermal amplification assay for detection of this important
517 ectoparasite of wombats and other animals. *PeerJ* 2018; **6**: e5291.
- 518 41. Xu J, Huang X, Dong X, et al. Serodiagnostic Potential of Alpha-Enolase From
519 *Sarcoptes scabiei* and Its Possible Role in Host-Mite Interactions. *Front Microbiol* 2018; **9**:
520 1024.
- 521 42. Arlian LG, Feldmeier H, Morgan MS. The Potential for a Blood Test for Scabies.
522 *PLoS Negl Trop Dis* 2015; **9**(10): e0004188.
- 523 43. Arlian LG, Morgan MS. A review of *Sarcoptes scabiei*: past, present and future.
524 *Parasit Vectors* 2017; **10**(1): 297.
- 525 44. Slutsky JB, Rabinovitz H, Grichnik JM, Marghoob AA. Reflectance confocal
526 microscopic features of dermatophytes, scabies, and demodex. *Archives of dermatology*
527 2011; **147**(8): 1008.
- 528 45. Cinotti E, Perrot JL, Labeille B, et al. Reflectance confocal microscopy for
529 quantification of *Sarcoptes scabiei* in Norwegian scabies. *Journal of the European Academy*
530 *of Dermatology and Venereology : JEADV* 2013; **27**(2): e176-8.
- 531 46. Cinotti E, Labeille B, Cambazard F, et al. Videodermoscopy compared to reflectance
532 confocal microscopy for the diagnosis of scabies. *Journal of the European Academy of*
533 *Dermatology and Venereology : JEADV* 2016; **30**(9): 1573-7.
- 534 47. Micali G, Lacarrubba F, Verzi AE, Nasca MR. Low-cost equipment for diagnosis and
535 management of endemic scabies outbreaks in underserved populations. *Clin Infect Dis* 2015;
536 **60**(2): 327-9.
- 537 48. Miller H, Trujillo-Trujillo J, Feldmeier H. In Situ Diagnosis of Scabies Using a
538 Handheld Digital Microscope in Resource-Poor Settings-A Proof-of-Principle Study in the
539 Amazon Lowland of Colombia. *Trop Med Infect Dis* 2018; **3**(4).

- 540 49. Courtright P, Rotondo LA, MacArthur C, et al. Strengthening the links between
541 mapping, planning and global engagement for disease elimination: lessons learnt from
542 trachoma. *Br J Ophthalmol* 2018; **102**(10): 1324-7.
- 543 50. Trotignon G, Jones E, Engels T, et al. The cost of mapping trachoma: Data from the
544 Global Trachoma Mapping Project. *PLoS Negl Trop Dis* 2017; **11**(10): e0006023.
- 545 51. Marks M, Engelman D, Romani L, et al. Exploration of a simplified clinical
546 examination for scabies to support public health decision-making. *PLoS Negl Trop Dis* 2018;
547 **12**(12): e0006996.
- 548 52. Negrel AD, Mariotti SP. Trachoma rapid assessment: rationale and basic principles.
549 *Community Eye Health* 1999; **12**(32): 51-3.
- 550 53. Ngondi J, Reacher M, Matthews F, Brayne C, Emerson P. Trachoma survey methods:
551 a literature review. *Bull World Health Organ* 2009; **87**(2): 143-51.
- 552 54. Solomon AW, Pavluck AL, Courtright P, et al. The global trachoma mapping project:
553 methodology of a 34-country population-based study. *Ophthalmic Epidemiol* 2015; **22**(3):
554 214-25.
- 555 55. Solomon AW, Willis R, Pavluck AL, et al. Quality Assurance and Quality Control in
556 the Global Trachoma Mapping Project. *Am J Trop Med Hyg* 2018.
- 557 56. Engelman D, Fuller LC, Solomon AW, et al. Opportunities for integrated control of
558 neglected tropical diseases that affect the skin. *Trends Parasitol* 2016; **32**(11): 843-54.
- 559 57. Finn TP, Stewart BT, Reid HL, et al. Integrated rapid mapping of neglected tropical
560 diseases in three States of South Sudan: survey findings and treatment needs. *PLoS One*
561 2012; **7**(12): e52789.
- 562 58. Smith JL, Sturrock HJ, Olives C, Solomon AW, Brooker SJ. Comparing the
563 performance of cluster random sampling and integrated threshold mapping for targeting
564 trachoma control, using computer simulation. *PLoS Negl Trop Dis* 2013; **7**(8): e2389.
- 565 59. Sheehan JP, Gebresillasie S, Shiferaw A, et al. School-Based versus Community-
566 Based Sampling for Trachoma Surveillance. *Am J Trop Med Hyg* 2018; **99**(1): 150-4.
- 567 60. Clucas DB, Carville KS, Connors C, Currie BJ, Carapetis JR, Andrews RM. Disease
568 burden and health-care clinic attendances for young children in remote aboriginal
569 communities of northern Australia. *Bull World Health Organ* 2008; **86**(4): 275-81.
- 570 61. Thornley S, Marshall R, Jarrett P, Sundborn G, Reynolds E, Schofield G. Scabies is
571 strongly associated with acute rheumatic fever in a cohort study of Auckland children. *J*
572 *Paediatr Child Health* 2018; **54**(6): 625-32.
- 573 62. Banerji A. Scabies. *Paediatr Child Health* 2015; **20**(7): 395-402.

- 574 63. Kouotou EA, Nansseu JRN, Sangare A, et al. Burden of human scabies in sub-
575 Saharan African prisons: Evidence from the west region of Cameroon. *The Australasian*
576 *journal of dermatology* 2018; **59**(1): e6-e10.
- 577 64. Ribeiro Fde A, Taciro E, Guerra MR, Eckley CA. Oral ivermectin for the treatment
578 and prophylaxis of scabies in prison. *The Journal of dermatological treatment* 2005; **16**(3):
579 138-41.
- 580 65. Arnaud A, Chosidow O, Detrez MA, et al. Prevalences of scabies and pediculosis
581 corporis among homeless people in the Paris region: results from two randomized cross-
582 sectional surveys (HYTPEAC study). *Br J Dermatol* 2016; **174**(1): 104-12.
- 583 66. Beeres DT, Ravensbergen SJ, Heidema A, et al. Efficacy of ivermectin mass-drug
584 administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort
585 study between January 2014 - March 2016. *PLoS Negl Trop Dis* 2018; **12**(5): e0006401.
- 586 67. Goodman LF, Jensen GW, Galante JM, Farmer DL, Tache S. A cross-sectional
587 investigation of the health needs of asylum seekers in a refugee clinic in Germany. *BMC Fam*
588 *Pract* 2018; **19**(1): 64.
- 589 68. Bloch-Infanger C, Battig V, Kremo J, et al. Increasing prevalence of infectious
590 diseases in asylum seekers at a tertiary care hospital in Switzerland. *PLoS One* 2017; **12**(6):
591 e0179537.
- 592 69. Hotez PJ. NTDs V.2.0: "blue marble health"--neglected tropical disease control and
593 elimination in a shifting health policy landscape. *PLoS Negl Trop Dis* 2013; **7**(11): e2570.
- 594 70. Engelman D, Steer AC. Diagnosis, treatment, and control of scabies: can we do
595 better? *Lancet Infect Dis* 2018; **18**(8): 822-3.
- 596 71. Cassell JA, Middleton J, Nalabanda A, et al. Scabies outbreaks in ten care homes for
597 elderly people: a prospective study of clinical features, epidemiology, and treatment
598 outcomes. *Lancet Infect Dis* 2018; **18**(8): 894-902.
- 599 72. White LC, Lanza S, Middleton J, et al. The management of scabies outbreaks in
600 residential care facilities for the elderly in England: a review of current health protection
601 guidelines. *Epidemiol Infect* 2016; **144**(15): 3121-30.
- 602 73. Mounsey KE, Murray HC, King M, Oprescu F. Retrospective analysis of institutional
603 scabies outbreaks from 1984 to 2013: lessons learned and moving forward. *Epidemiol Infect*
604 2016; **144**(11): 2462-71.
- 605 74. Lydeamore MJ, Campbell PT, Cuninghame W, et al. Calculation of the age of the first
606 infection for skin sores and scabies in five remote communities in northern Australia.
607 *Epidemiol Infect* 2018; **146**(9): 1194-201.

- 608 75. Lydeamore MJ, Campbell PT, Regan DG, et al. A biological model of scabies
609 infection dynamics and treatment informs mass drug administration strategies to increase the
610 likelihood of elimination. *Math Biosci* 2018.
- 611 76. Mimouni D, Gdalevich M, Mimouni FB, Haviv J, Ashkenazi I. The epidemiologic
612 trends of scabies among Israeli soldiers: a 28-year follow-up. *Int J Dermatol* 1998; **37**(8):
613 586-7.
- 614 77. Savin JA. Scabies in Edinburgh from 1815 to 2000. *J R Soc Med* 2005; **98**(3): 124-9.
- 615 78. Roberts LJ, Huffam SE, Walton SF, Currie BJ. Crusted scabies: clinical and
616 immunological findings in seventy-eight patients and a review of the literature. *J Infect* 2005;
617 **50**(5): 375-81.
- 618 79. Kearns TM, Speare R, Cheng AC, et al. Impact of an Ivermectin Mass Drug
619 Administration on Scabies Prevalence in a Remote Australian Aboriginal Community. *PLoS*
620 *Negl Trop Dis* 2015; **9**(10): e0004151.
- 621 80. Walton SF, Beroukas D, Roberts-Thomson P, Currie BJ. New insights into disease
622 pathogenesis in crusted (Norwegian) scabies: the skin immune response in crusted scabies. *Br*
623 *J Dermatol* 2008; **158**(6): 1247-55.
- 624 81. Lokuge B, Kopczynski A, Woltmann A, et al. Crusted scabies in remote Australia, a
625 new way forward: lessons and outcomes from the East Arnhem Scabies Control Program.
626 *Med J Aust* 2014; **200**(11): 644-8.
- 627 82. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain
628 that links the heart to the throat? *Lancet Infect Dis* 2004; **4**(4): 240-5.
- 629 83. Engelman D, Hofer A, Davis JS, et al. Invasive *Staphylococcus aureus* Infections in
630 Children in Tropical Northern Australia. *JPIDS* 2014; **3**(4): 304-11.
- 631 84. Jenney A, Holt D, Ritika R, et al. The clinical and molecular epidemiology of
632 *Staphylococcus aureus* infections in Fiji. *BMC Infect Dis* 2014; **14**: 160.
- 633 85. Eison TM, Ault BH, Jones DP, Chesney RW, Wyatt RJ. Post-streptococcal acute
634 glomerulonephritis in children: clinical features and pathogenesis. *Pediatr Nephrol* 2011;
635 **26**(2): 165-80.
- 636 86. Hoy WE, White AV, Dowling A, et al. Post-streptococcal glomerulonephritis is a
637 strong risk factor for chronic kidney disease in later life. *Kidney Int* 2012; **81**(10): 1026-32.
- 638 87. Chung SD, Wang KH, Huang CC, Lin HC. Scabies increased the risk of chronic
639 kidney disease: a 5-year follow-up study. *Journal of the European Academy of Dermatology*
640 *and Venereology : JEADV* 2014; **28**(3): 286-92.

- 641 88. Wang D, Li L, Wei L, Liu Y, Sun S. Acute postinfectious glomerulonephritis
642 associated with scabies in the elderly: A case report. *Parasitol Int* 2017; **66**(6): 802-5.
- 643 89. Svartman M, Finklea JF, Earle DP, Potter EV, Poon-King T. Epidemic scabies and
644 acute glomerulonephritis in Trinidad. *Lancet* 1972; **1**(7744): 249-51.
- 645 90. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National
646 Burden of Rheumatic Heart Disease, 1990-2015. *N Engl J Med* 2017; **377**(8): 713-22.
- 647 91. World Health Organization. 71st World Health Assembly adopts resolution calling for
648 greater action on rheumatic heart disease. May 25, 2018 2018.
649 <http://www.who.int/ncds/management/rheumatic-heart-disease-resolution/en/> (accessed
650 September 10, 2018).
- 651 92. Jackson A, Heukelbach J, Filho AF, Junior Ede B, Feldmeier H. Clinical features and
652 associated morbidity of scabies in a rural community in Alagoas, Brazil. *Trop Med Int Health*
653 2007; **12**(4): 493-502.
- 654 93. Worth C, Heukelbach J, Fengler G, Walter B, Lisenfeld O, Feldmeier H. Impaired
655 quality of life in adults and children with scabies from an impoverished community in Brazil.
656 *Int J Dermatol* 2012; **51**: 275–82.
- 657 94. Litt E, Baker MC, Molyneux D. Neglected tropical diseases and mental health: a
658 perspective on comorbidity. *Trends Parasitol* 2012; **28**(5): 195-201.
- 659 95. Cinotti E, Perrot JL, Labeille B, et al. Inefficacy of alcohol-based hand rub on mites
660 in a patient with hyperkeratotic scabies. *Clin Exp Dermatol* 2015; **40**(2): 177-81.
- 661 96. Steer AC, Romani L, Kaldor JM. Mass Drug Administration for Scabies Control. *N*
662 *Engl J Med* 2016; **374**(17): 1690.
- 663 97. Middleton J, Cassell JA, Jones CI, Lanza S, Head MG, Walker SL. Scabies control:
664 the forgotten role of personal hygiene - Authors' reply. *Lancet Infect Dis* 2018; **18**(10): 1068-
665 9.
- 666 98. Hay RJ, Estrada Castanon R, Alarcon Hernandez H, et al. Wastage of family income
667 on skin disease in Mexico. *BMJ* 1994; **309**(6958): 848.
- 668 99. La Vincente S, Kearns T, Connors C, Cameron S, Carapetis J, Andrews R.
669 Community management of endemic scabies in remote aboriginal communities of northern
670 Australia: low treatment uptake and high ongoing acquisition. *PLoS Negl Trop Dis* 2009;
671 **3**(5): e444.
- 672 100. Johnstone P, Strong M. Scabies. *BMJ Clin Evid* 2014; **2014**.
- 673 101. Gopinath H, Aishwarya M, Karthikeyan K. Tackling scabies: novel agents for a
674 neglected disease. *Int J Dermatol* 2018.

- 675 102. Thomas J, Christenson JK, Walker E, Baby KE, Peterson GM. Scabies-An ancient
676 itch that is still rampant today. *J Clin Pharm Ther* 2017; **42**(6): 793-9.
- 677 103. Walton SF, McKinnon M, Pizzutto S, Dougall A, Williams E, Currie BJ. Acaricidal
678 activity of *Melaleuca alternifolia* (tea tree) oil: in vitro sensitivity of *Sarcoptes scabiei* var
679 *hominis* to terpinen-4-ol. *Archives of dermatology* 2004; **140**(5): 563-6.
- 680 104. Pasay C, Mounsey K, Stevenson G, et al. Acaricidal activity of eugenol based
681 compounds against scabies mites. *PLoS One* 2010; **5**(8): e12079.
- 682 105. Thomas J, Carson CF, Peterson GM, et al. Therapeutic Potential of Tea Tree Oil for
683 Scabies. *Am J Trop Med Hyg* 2016; **94**(2): 258-66.
- 684 106. Thomas J, Davey R, Peterson GM, et al. Treatment of scabies using a tea tree oil-
685 based gel formulation in Australian Aboriginal children: protocol for a randomised controlled
686 trial. *BMJ Open* 2018; **8**(5): e018507.
- 687 107. Fang F, Candy K, Melloul E, et al. In vitro activity of ten essential oils against
688 *Sarcoptes scabiei*. *Parasit Vectors* 2016; **9**(1): 594.
- 689 108. Rutherford T, Nixon R, Tam M, Tate B. Allergy to tea tree oil: retrospective review
690 of 41 cases with positive patch tests over 4.5 years. *The Australasian journal of dermatology*
691 2007; **48**(2): 83-7.
- 692 109. Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies.
693 *Cochrane Database Syst Rev* 2018; **4**: Cd012994.
- 694 110. Thylefors B, Alleman MM, Twum-Danso NA. Operational lessons from 20 years of
695 the Mectizan Donation Program for the control of onchocerciasis. *Trop Med Int Health* 2008;
696 **13**(5): 689-96.
- 697 111. Chaccour C, Barrio A, Gil Royo AG, et al. Screening for an ivermectin slow-release
698 formulation suitable for malaria vector control. *Malar J* 2015; **14**: 102.
- 699 112. Mounsey KE, Bernigaud C, Chosidow O, McCarthy JS. Prospects for Moxidectin as a
700 New Oral Treatment for Human Scabies. *PLoS Negl Trop Dis* 2016; **10**(3): e0004389.
- 701 113. Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety,
702 tolerability, and pharmacokinetics in humans. *J Clin Pharmacol* 2003; **43**(10): 1108-15.
- 703 114. Bernigaud C, Fang F, Fischer K, et al. Preclinical study of single-dose moxidectin, a
704 new oral treatment for scabies: efficacy, safety, and pharmacokinetics compared to two-dose
705 ivermectin in a porcine model. *PLoS Negl Trop Dis* 2016; **10**(10): e0005030.
- 706 115. Olliaro PL, Kuesel AC, Halleux CM, Sullivan M, Reeder JC. Creative use of the
707 priority review voucher by public and not-for-profit actors delivers the first new FDA-

708 approved treatment for river blindness in 20 years. *PLoS Negl Trop Dis* 2018; **12**(11):
709 e0006837.

710 116. Medicines Development for Global Health. Moxidectin Program. 2018.
711 <https://www.medicinesdevelopment.com/development-programs.htm> (accessed 3 August
712 2018).

713 117. Wilkins AL, Steer AC, Cranswick N, Gwee A. Is it safe to use ivermectin in children
714 less than five years of age and weighing less than 15 kg? *Arch Dis Child* 2018; **103**(5): 514-9.

715 118. Becourt C, Marguet C, Balguerie X, Joly P. Treatment of scabies with oral ivermectin
716 in 15 infants: a retrospective study on tolerance and efficacy. *Br J Dermatol* 2013; **169**(4):
717 931-3.

718 119. Chaccour C, Hammann F, Rabinovich NR. Ivermectin to reduce malaria transmission
719 I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety.
720 *Malar J* 2017; **16**(1): 161.

721 120. Ndyomugenyi R, Kabatereine N, Olsen A, Magnussen P. Efficacy of ivermectin and
722 albendazole alone and in combination for treatment of soil-transmitted helminths in
723 pregnancy and adverse events: a randomized open label controlled intervention trial in
724 Masindi district, western Uganda. *Am J Trop Med Hyg* 2008; **79**(6): 856-63.

725 121. Pacque M, Munoz B, Poetschke G, Foose J, Greene BM, Taylor HR. Pregnancy
726 outcome after inadvertent ivermectin treatment during community-based distribution. *Lancet*
727 1990; **336**(8729): 1486-9.

728 122. Gyapong JO, Chinbuah MA, Gyapong M. Inadvertent exposure of pregnant women to
729 ivermectin and albendazole during mass drug administration for lymphatic filariasis. *Trop*
730 *Med Int Health* 2003; **8**(12): 1093-101.

731 123. Chippaux JP, Gardon-Wendel N, Gardon J, Ernould JC. Absence of any adverse
732 effect of inadvertent ivermectin treatment during pregnancy. *Trans R Soc Trop Med Hyg*
733 1993; **87**(3): 318.

734 124. Brown KR. Changes in the use profile of Mectizan: 1987-1997. *Ann Trop Med*
735 *Parasitol* 1998; **92 Suppl 1**: S61-4.

736 125. Scabicides et grossesse (Scabies in pregnancy). July 6, 2018.
737 https://lecrat.fr/spip.php?page=article&id_article=585 (accessed October 30 2018).

738 126. Kamgno J, Pion SD, Chesnais CB, et al. A Test-and-Not-Treat Strategy for
739 Onchocerciasis in Loa loa-Endemic Areas. *N Engl J Med* 2017; **377**(21): 2044-52.

740 127. Richards FO, Jr. Mass Administration of Ivermectin in Areas Where Loa loa Is
741 Endemic. *N Engl J Med* 2017; **377**(21): 2088-90.

- 742 128. Romani L, Marks M, Sokana O, et al. Feasibility and safety of mass drug
743 coadministration with azithromycin and ivermectin for the control of neglected tropical
744 diseases: a single-arm intervention trial. *Lancet Glob Health* 2018; **6**(10): e1132-e8.
- 745 129. Coulibaly YI, Dicko I, Keita M, et al. A cluster randomized study of the safety of
746 integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso,
747 Mali. *PLoS Negl Trop Dis* 2013; **7**(5): e2221.
- 748 130. Marks M, Toloka H, Baker C, et al. Randomised trial of community treatment with
749 azithromycin and ivermectin mass drug administration for control of scabies and impetigo.
750 *Clin Infect Dis* 2018.
- 751 131. Fischer PU, King CL, Jacobson JA, Weil GJ. Potential Value of Triple Drug Therapy
752 with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of
753 Lymphatic Filariasis and Onchocerciasis in Africa. *PLoS Negl Trop Dis* 2017; **11**(1):
754 e0005163.
- 755 132. Thomsen EK, Sanuku N, Baea M, et al. Efficacy, Safety, and Pharmacokinetics of
756 Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of
757 Bancroftian Filariasis. *Clin Infect Dis* 2016; **62**(3): 334-41.
- 758 133. World Health Organization. Alternative mass drug administration regimens to
759 eliminate lymphatic filariasis. Geneva: WHO, 2017.
- 760 134. King CL, Suamani J, Sanuku N, et al. A Trial of a Triple-Drug Treatment for
761 Lymphatic Filariasis. *N Engl J Med* 2018; **379**(19): 1801-10.
- 762 135. Khalil S, Abbas O, Kibbi AG, Kurban M. Scabies in the age of increasing drug
763 resistance. *PLoS Negl Trop Dis* 2017; **11**(11): e0005920.
- 764 136. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo and
765 in vitro ivermectin resistance in *Sarcoptes scabiei*. *Clin Infect Dis* 2004; **39**(1): e8-12.
- 766 137. Mounsey KE, Holt DC, McCarthy JS, Currie BJ, Walton SF. Longitudinal evidence
767 of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic
768 communities. *Archives of dermatology* 2009; **145**(7): 840-1.
- 769 138. Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug
770 administration to global health: past, present and future. *Philos Trans R Soc Lond B Biol Sci*
771 2014; **369**(1645): 20130434.
- 772 139. Rabinovich NR. Ivermectin: repurposing an old drug to complement malaria vector
773 control. *Lancet Infect Dis* 2018; **18**(6): 584-5.
- 774 140. Smit MR, Ochomo EO, Aljayyousi G, et al. Safety and mosquitocidal efficacy of
775 high-dose ivermectin when co-administered with dihydroartemisinin-piperazine in Kenyan

776 adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-
777 controlled trial. *Lancet Infect Dis* 2018; **18**(6): 615-26.

778 141. Prichard RK. Ivermectin resistance and overview of the Consortium for Anthelmintic
779 Resistance SNPs. *Expert Opin Drug Discov* 2007; **2**(s1): S41-52.

780 142. Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF. Scabies: molecular
781 perspectives and therapeutic implications in the face of emerging drug resistance. *Future*
782 *Microbiol* 2008; **3**(1): 57-66.

783 143. McNair CM. Ectoparasites of medical and veterinary importance: drug resistance and
784 the need for alternative control methods. *J Pharm Pharmacol* 2015; **67**(3): 351-63.

785 144. Guideline for the diagnosis and treatment of scabies in Japan (third edition):
786 Executive Committee of Guideline for the Diagnosis and Treatment of Scabies. *The Journal*
787 *of dermatology* 2017; **44**(9): 991-1014.

788 145. Salavastru CM, Chosidow O, Boffa MJ, Janier M, Tiplica GS. European guideline for
789 the management of scabies. *Journal of the European Academy of Dermatology and*
790 *Venereology : JEADV* 2017; **31**(8): 1248-53.

791 146. Sunderkotter C, Feldmeier H, Folster-Holst R, et al. S1 guidelines on the diagnosis
792 and treatment of scabies - short version. *J Dtsch Dermatol Ges* 2016; **14**(11): 1155-67.

793 147. Quilty S, Kaye TS, Currie BJ. Crusted scabies in northern and central Australia - now
794 is the time for eradication. *Med J Aust* 2017; **206**(2): 96.

795 148. Davis JS, McGloughlin S, Tong SY, Walton SF, Currie BJ. A novel clinical grading
796 scale to guide the management of crusted scabies. *PLoS Negl Trop Dis* 2013; **7**(9): e2387.

797 149. Chosidow O, Bernigaud C, Do-Pham G. High-dose ivermectin in malaria and other
798 parasitic diseases: a new step in the development of a neglected drug. *Parasite* 2018; **25**: 33.

799 150. Taplin D, Arrue C, Walker J, Roth W, Rivera A. Eradication of scabies with a single
800 treatment schedule. *J Am Acad Dermatol* 1983; **9**(546-50).

801 151. Engelman D, Steer AC. Control Strategies for Scabies. *Trop Med Infect Dis* 2018;
802 **3**(3).

803 152. Thean LJ, Engelman D, Kaldor J, Steer AC. Scabies: New Opportunities for
804 Management and Population Control. *Pediatr Infect Dis J* 2018.

805 153. Andrews RM, Kearns T, Connors C, et al. A regional initiative to reduce skin
806 infections amongst aboriginal children living in remote communities of the Northern
807 Territory, Australia. *PLoS Negl Trop Dis* 2009; **3**(11): e554.

808 154. Lawrence G, Leafasia J, Sheridan J, et al. Control of scabies, skin sores and
809 haematuria in children in the Solomon Islands: another role for ivermectin. *Bull World Health*
810 *Organ* 2005; **83**(1): 34-42.

811 155. Engelman D, Martin DL, Hay RJ, et al. Opportunities to investigate the effects of
812 ivermectin mass drug administration on scabies. *Parasit Vectors* 2013; **6**: 106.

813 156. Mohammed KA, Deb RM, Stanton MC, Molyneux DH. Soil transmitted helminths
814 and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic
815 filariasis--a rapid assessment methodology to assess impact. *Parasit Vectors* 2012; **5**: 299.

816 157. Martin D, Wiegand R, Goodhew B, Lammie P, Mkocho H, Kasubi M. Impact of
817 Ivermectin Mass Drug Administration for Lymphatic Filariasis on Scabies in Eight Villages
818 in Kongwa District, Tanzania. *Am J Trop Med Hyg* 2018.

819 158. Romani L, Whitfield MJ, Koroivueta J, et al. Mass Drug Administration for Scabies
820 Control in a Population with Endemic Disease. *N Engl J Med* 2015; **373**(24): 2305-13.

821 159. Romani L, Kaldor J, Steer A. Sustained reduction of scabies two years after mass
822 drug administration. *N Engl J Med* 2019 (in press).

823 160. Mitja O, Marks M, Bertran L, et al. Integrated Control and Management of Neglected
824 Tropical Skin Diseases. *PLoS Negl Trop Dis* 2017; **11**(1): e0005136.

825 161. Liu X, Walton S, Mounsey K. Vaccine against scabies: necessity and possibility.
826 *Parasitology* 2014; **141**(6): 725-32.

827 162. Casais R, Granda V, Balseiro A, et al. Vaccination of rabbits with immunodominant
828 antigens from *Sarcoptes scabiei* induced high levels of humoral responses and pro-
829 inflammatory cytokines but confers limited protection. *Parasit Vectors* 2016; **9**(1): 435.

830 163. Chu BK, Deming M, Biritwum NK, et al. Transmission assessment surveys (TAS) to
831 define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation.
832 *PLoS Negl Trop Dis* 2013; **7**(12): e2584.

833 164. Mectizan Donation Program. Guide for Donations of Mectizan® to Accelerate the
834 Elimination of Lymphatic Filariasis in Countries where Onchocerciasis is not co-endemic.
835 2017. [https://mectizan.org/news-resources/mec-guide-for-donations-of-mectizan-in-ida-](https://mectizan.org/news-resources/mec-guide-for-donations-of-mectizan-in-ida-countries/)
836 [countries/](https://mectizan.org/news-resources/mec-guide-for-donations-of-mectizan-in-ida-countries/) (accessed October 8, 2018).

837

838

839

840 **Search strategy and selection criteria**

841 References for this review were identified through searches of PubMed for articles published
842 from January, 1990, to March, 2019, using the terms “scabies” and “*Sarcoptes scabiei*.”
843 Reference lists of identified manuscripts were reviewed to identify additional relevant
844 material. No language restrictions were imposed.

845

846

847

848

849 **List of Acronyms**

850 DALY, disability-adjusted life year

851 ELISA, enzyme-linked immunosorbent assay

852 GBD, Global Burden of Disease

853 IACS, International Alliance for the Control of Scabies

854 IDA, ivermectin, diethylcarbamazine and albendazole

855 LMIC, low- and middle-income countries

856 NTD, neglected tropical disease

857 MDA, mass drug administration

858 US FDA, United States Food and Drug Administration

859 WHO, World Health Organization

860

861 **Panel 1. Key Research Questions**

862 Diagnosis

- 863 • What is the accuracy and reproducibility of diagnosis using the 2018 IACS Criteria?
- 864 • Can a limited skin examination protocol by non-expert health workers provide
- 865 acceptable accuracy for estimating prevalence?
- 866 • Can accurate skin-sample or blood tests be developed for scabies diagnosis?

867 Epidemiology and mapping

- 868 • What is the global burden of scabies? Which countries have the highest burdens of
- 869 scabies?
- 870 • What is the at-risk population living in highly-endemic settings?
- 871 • Are there identifiable risk factors for areas of high prevalence?
- 872 • What is the correlation between prevalence in school-attending children and the
- 873 community?

874 Transmission and complications

- 875 • What are the transmission dynamics of scabies?
- 876 • To what extent does crusted scabies drive transmission in highly endemic settings?
- 877 • What is the association between scabies and impetigo outside the Pacific region?

878 Social and economic

- 879 • What is the social burden of scabies as perceived and understood by affected
- 880 communities?
- 881 • What is the acceptability of MDA for scabies to affected communities?
- 882 • What approaches can effectively engage communities to support scabies control
- 883 initiatives?

884 Treatments

- 885 • Can ivermectin or other oral agents be safely administered to children of height < 90
- 886 cm, weight <15 kg or age <5 years?
- 887 • Are novel topical agents as effective, better tolerated or more affordable than
- 888 permethrin?
- 889 • What is the effectiveness of moxidectin for individual treatment and MDA for
- 890 scabies?

891 Mass drug administration for scabies

- 892 • What is the optimal dose and dosing strategy of ivermectin for MDA?
- 893 • What is the optimal interval between rounds of MDA?
- 894 • What is the impact of MDA for scabies on the burden of impetigo, severe bacterial
- 895 soft-tissue and systemic infections, glomerulonephritis and rheumatic heart disease?
- 896 • Under what conditions would MDA for scabies be cost-effective?
- 897 • How can ivermectin-based MDA for scabies be safely and effectively integrated
- 898 and/or co-administered with MDA for other NTDs?

899 Control strategy

- 900 • In what circumstances (threshold scabies prevalence or other factors) should MDA
- 901 and intensified case management strategies be used?
- 902 • If MDA is not being used, how can intensified case management be implemented?

- 903
- What are the effects of ivermectin-based MDA programs for other NTDs on scabies?
904 What happens to scabies prevalence when these programs cease?
 - What is the feasibility and effect of adding permethrin treatment of young children to
905 existing ivermectin-based MDA programs for other NTDs?
906
 - What, if any, environmental measures should be recommended?
907

908

909

910 **Panel 2. Key Programmatic Issues**

911 Epidemiology

- 912 • Development of a protocol and training package for scabies mapping
- 913 • Mapping scabies prevalence using standardised methods, focusing on LMIC
- 914 • Integrated surveys with other NTD and health programs
- 915 • Surveillance strategies for potential outbreaks in high-risk settings
- 916 • Understanding high-burden groups within high-income settings

917

918 Population-level Control

- 919 • Interim guidance for public health control of scabies, including thresholds for starting
920 and stopping MDA, number and frequency of rounds, drugs and doses.
- 921 • Interim guidance on control of scabies outbreaks in institutions and communities
- 922 • Monitoring and evaluation strategy for impact of interventions on scabies
- 923 • Monitoring and evaluation strategy for impact of interventions on scabies
924 complications and other conditions.
- 925 • Monitoring for resistance

926

927 Strategy

- 928 • Define a global control strategy with targets
- 929 • Affordable and reliable access to oral and topical medications for treatment
- 930 • Ivermectin listing on WHO Essential Medicines List for scabies indication
- 931 • Integration with programs for other NTDs and other health programs
- 932 • Develop proposal for a future World Health Assembly resolution

933

934

FIGURE LEGEND

Figure 1: Child's feet with skin manifestations of scabies infestation and secondary pyoderma

Photo courtesy Millicent Osti

Figure 2: Prevalence of scabies in children and adolescents younger than 19 years

Prevalence is shown at the country level, using available data from Romani *et al.*, 2015⁴ and updated with additional references.^{8,10-17} Subnational variation exists but is not represented in the map.

Figure 3: Primary and secondary effects of scabies infestation